Recent publications show that classic hepatoblastoma (HBL) is the result of failure of hepatic stem cells to differentiate into hepatocytes, while hepatocellular carcinoma (HCC) is caused by the dedifferentiation of hepatocytes into cancer stem cells. However, the mechanisms of aggressive HBL and the mechanisms that cause dedifferentiation of hepatocytes into cancer stem cells are unknown. We found that, similar to HCC but opposite to classic HBL, aggressive HBL is the result of dedifferentiation of hepatocytes into cancer stem cells. In both cases of liver cancer, the dephosphorylation of tumor suppressor protein CCAAT/enhancer binding protein a (C/EBPa) at Ser193 (Ser190 in human protein) or mutation of Ser193 to Ala results in a modified protein with oncogenic activities. We have investigated liver cancer in a mouse model C/EBPa-S193A, in a large cohort of human HBL samples, and in Pten/p53 double knockout mice and found that these cancers are characterized by elevation of C/EBPa that is dephosphorylated at Ser190/193. We found that dephosphorylated C/EBPa creates preneoplastic foci with cancer stem cells that give rise to HCC and aggressive HBL. C/EBPadependent dedifferentiation of hepatocytes into cancer stem cells includes increased proliferation of hepatocytes, followed by generation of multinucleated hepatocytes and subsequent appearance of hepatocytes with delta-like 1 homolog-positive intranuclear inclusions. We further isolated C/EBPa-dependent multinucleated hepatocytes and found that they possess characteristics of tumor-initiating cells, including elevation of stem cell markers. C/EBPa-dependent cancer stem cells are observed in patients with aggressive HBL and in patients with a predisposition for liver cancer. Conclusion: The earliest steps of adult HCC and aggressive pediatric liver cancer have identical features that include conversion of the tumor suppressor C/EBPa into an oncogenic isoform, which further creates preneoplastic foci where hepatocytes dedifferentiate into cancer cells, giving rise to liver cancer. (HEPATOLOGY 2018;67:1857-1871.
T he origin of liver cancer is under intensive investigation; however, little is known about tumor-originating cell types and the mechanisms which initiate liver cancer. Early studies of hepatocellular carcinoma (HCC) suggested that progenitor cells give rise to liver cancer. Expansion of progenitor cells was found in mice with alterations of the Hippo pathway (1) and with liver-specific deletion of NF2. (2) In addition, He et al. have identified progenitor cells that form collagenase-resistant aggregates at very early stages of liver cancer, (3) suggesting that these progenitor cells give rise to liver cancer. However, recent studies demonstrated that HCC is quite heterogeneous, suggesting several different cell origins for the development of liver cancer. (4) Due to their capacity to proliferate and their remarkable plasticity to dedifferentiate into other cell types, hepatocytes have great potential to initiate liver cancer. (5) In fact, a recent article showed that hepatocytes are the main cells of origin of hepatotoxin-induced liver cancer. (6) The loss of p53 also resulted in dedifferentiation of hepatocytes into progenitor-like cells. (7) In addition, adult hepatocytes might trans-differentiate into biliary-like cells that produce liver cancer. (8) The development of liver cancer involves alterations of gene expression within multiple pathways. (9) (10) (11) The quiescent liver does not proliferate (5) and is protected from liver cancer by more than 20 tumor suppressor proteins. (12) However, many reports have revealed that tumor suppressor proteins are reduced in cancer by transcriptional repression (13) or by degradation through the ubiquitin proteasome system. (11, 12) Interestingly, recent reports show that tumor suppressor proteins are elevated in some cancers. For example, CCAAT/enhancer binding protein a (C/ EBPa) is elevated in some patients with HCC. (14) (15) (16) The activity of C/EBPa is regulated by phosphorylation at Ser193 (Ser190 in human protein). (11, 16, 17) Phosphorylation of C/EBPa at Ser193 enhances its tumor suppressor activities. (18, 19) However, phosphorylated Ser193 C/EBPa is eliminated by the oncogene gankyrin (Gank) during the development of liver cancer. (19) (20) (21) We recently generated C/EBPa-S193A mice and found that S193A livers lost mechanisms to stop liver proliferation. (22, 23) Pediatric liver cancer is far less investigated than HCC. Several reports have described transcriptome profiling in large cohorts of hepatoblastoma (HBL) patients. (24) (25) (26) (27) These studies revealed the significant role of c-myc and Wnt-b-catenin signaling and micro-RNAs in the development of HBL (24) (25) (26) ; however, HBL is a genetically simple tumor with 2.9 mutations per tumor, mainly in the b-catenin and NFE2L2 genes. (27) We also found that the farnesoid X receptor (FXR)-Gank-tumor suppressor axis plays an essential role in the development of HBL. (21) In this study, we examined activities of a dephosphorylated form of the tumor suppressor protein C/ EBPa, which is elevated in aggressive, chemotherapyresistant HBL. The dephosphorylation of mouse and human C/EBPa at Ser193/Ser190 converts this tumor suppressor into a protein with oncogenic activities. The oncogenic form of C/EBPa creates preneoplastic foci and initiates transformation of hepatocytes into stem-like cells within these foci. These mechanisms of liver cancer work in aggressive HBL and in HCC.
Materials and Methods

ANIMAL MODELS
Experiments with animals were approved by the Institutional Animal Care and Use Committee at Cincinnati Children's Hospital (protocol IACUC2014-0042). Wild-type (WT) and C/EBPa-S193A mice were bred in-house, with free access to food and water on a 12-hour dark/light cycle. Male mice were injected intraperitoneally with N-diethylnitrosamine (DEN) at a concentration of 50 lg/g body weight at 4 weeks of age at the time of weaning. Livers were harvested at 25, 28, and 30 weeks post-DEN injection to analyze tumor formation. C/EBPa-S193A generation and characterization have been described. (21) HBL AND HCC SAMPLES HBL samples and liver tissue from an individual with telomere shortening secondary to dyskeratosis congenita were acquired through the Cincinnati Children's Hospital Medical Center's Pathology
Biorepository. Among 51 HBL samples, we obtained six samples from patients with aggressive HBL that are characterized by very fast growth, by chemoresistance, and by poor postoperative prognosis. These HBL samples have been described in detail. (21) ANTIBODIES Antibodies (Abs) to Ki67 (MA5-99520), alphasmooth muscle actin (RB-9010-P), and cyclin D1 (RM-9104-S1) were from Thermo Scientific. Cytokeratin 19 (Troma-III) Ab was deposited by R. Kemler to DSHB Hybridoma Product TROMA-III. Cleaved caspase 3 (Asp 175) Ab came from Cell Signaling (9661S). Abs to hepatocyte nuclear factor 4 alpha (HNF4a; C-19; SC-6556), Gank (H-231; SC-8991), alpha-fetoprotein (AFP; SC-8399), and bcatenin (SC-7963) were from Santa Cruz Biotechnology Inc. Delta-like 1 homolog (DLK1; ab21682) and H3K9 Me Abs were from Abcam. Glutamine synthetase (610517) Ab was purchased from BD Biosciences. Abs to human phosphorylated S190-C/EBPa were generated in our lab and used previously. (28) Abs to Ser193 phosphorylated C/EBPa were purchased from Thermo Scientific (PA5-37342). Alcian blue and periodic acid-Schiff staining solutions were from Newcomer Supply. The Apoptag kit was from Millipore for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining.
WESTERN BLOTTING
Protein extracts were isolated from mouse and human livers as described. (18) (19) (20) Protein extracts (50-100 lg) were loaded on to 4%-20% gradient gels (Bio-Rad) and transferred to nitrocellulose membranes (Bio-Rad). Membranes were probed with corresponding antibodies. The results of western blotting analysis are presented as ratios of proteins to loading controls.
IMMUNOSTAINING
Liver sections were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and sectioned (6-lm sections). Mice were injected intraperitoneally with 66.5 mg/kg bromodeoxyuridine (BrdU) for histological examination 24 hours prior to tissue harvest. BrdU staining was performed using a BrdU uptake assay kit (Invitrogen). Sirius red staining was performed using the Picrosirius Red Stain Kit from Polysciences, Inc.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-BASED EXAMINATION OF PROTEIN-PROTEIN COMPLEXES
Nuclear extracts from background and tumor sections of HBL samples or from WT and S193A mice were fractionated by size exclusion chromatography (SEC) using an SEC400 column (BioRad) as described. (18) (19) (20) (21) Optical density (280 nM) was monitored for each SEC run and compared for tumor and background sections. The location of C/EBPa and retinoblastoma (Rb) in SEC fractions was determined by western blotting with specific Abs. For detection of protein-protein complexes, Rb was immunoprecipitated from SEC fractions, and the immunoprecipitates (IPs) were probed with Abs to C/EBPa.
QUANTITATIVE RT-PCR
Total RNA was isolated from mouse and human livers using the RNEasy Plus mini kit (Qiagen) according to the manufacturer's instructions. Complementary DNA was synthesized with 2 lg of total RNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). Gene expression analysis was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems) in a total volume of 10 lL containing 5 lL Master Mix, 1.5 lL water, 3 lL complementary DNA template, and 0.5 lL of the gene-specific TaqMan Assay probe mixture. TaqMan probe mixtures were purchased from Applied Biosystems.
LIVER PERFUSION AND HEPATOCYTE ISOLATION
The livers of S193A and WT age-matched control mice were perfused as described in Shin et al. (29) to obtain a single-cell suspension for cell culture and flow cytometry.
FLOW CYTOMETRY
Flow cytometry was used on S193A mice that formed tumors spontaneously in addition to WT agematched control mice to sort large hepatocytes based on size and DNA content. Abs used for this procedure were 7-amino-actinomycin D (A1310), which serves as a cell viability marker, and Hoechst stain (62249), a nuclear marker that sorts by DNA content. Both Abs were purchased from Thermo Scientific.
STATISTICAL ANALYSIS
All values are presented as means 6 SD. Differences between animal groups and background and tumor sections of HBL were determined using a Student t test. P < 0.05 was considered statistically significant.
Results
AGGRESSIVE HBL IS CHARACTERIZED BY ELEVATION OF C/EBPa DEPHOSPHORYLATED AT Ser190
We analyzed C/EBPa in 51 patients with HBL and identified 6 patients with aggressive HBL that have dramatically elevated dephosphorylated S190-C/EBPa. The characterization of these HBLs and the mechanisms that activate transcription of C/EBPa are described elsewhere (L. Valanejad and N. Timchenko, unpublished) . Here, we examined the biological consequences of the elevation of dephosphorylated C/EBPa. Figure 1A shows a western blot of livers of 17 HBL patients. Protein levels of C/EBPa are reduced in all samples with classic, chemotherapy-sensitive HBL; but 4 patients with aggressive HBL showed significant elevation of C/EBPa. Reprobe of the same filter with Abs to phosphorylated S190-C/EBPa revealed that the elevated C/EBPa is dephosphorylated at Ser190 (Fig. 1A,B) . C/EBPa displays its activity by making complexes with other proteins (17) (18) (19) ; therefore, we examined C/EBPa complexes using SEC. Optical density profiles showed that aggressive HBL contains increased amounts of protein-protein complexes in the area of high-molecular weight (MW) complexes (Fig. 1C) . We found that C/EBPa-Rb complexes are abundant in areas of high-MW complexes in HBL samples, while background regions do not have these complexes (Fig. 1D ). Examination of SEC fractions with antibodies specific to phosphorylated S190-C/EBPa showed no signals, suggesting that C/EBPa-Rb complexes are formed by the dephosphorylated S190 isoform of C/EBPa. These results demonstrate that aggressive HBL is characterized by an elevation of dephosphorylated S190-C/EBPa and by accumulation of C/EBPa-Rb complexes that are formed by dephosphorylated S190 C/EBPa.
DEN-TREATED C/EBPa-S193A MICE DEVELOP HEPATIC CARCINOGENESIS MORE RAPIDLY THAN WT MICE
Our studies have shown that C/EBPa is dephosphorylated at S190 in some HCC samples. (17) These results, and those shown in Fig. 1 , suggested that dephosphorylated S190-C/EBPa may play a critical role in the development of aggressive HBL and HCC. To examine the role of dephosphorylated C/EBPa in liver cancer, we used C/EBPa-S193A mice that mimic dephosphorylation of C/EBPa. (22) We began by examining the development of cancer under DEN-mediated carcinogenesis so that early stages of liver cancer could be determined more precisely. To avoid strain-specific differences in the development of liver cancer, we used WT and S193A homozygous male littermates. Five mice of each genotype were treated with DEN ( Fig.  2A ). Animals were sacrificed at 25, 28, and 30 weeks; and livers were grossly and histologically examined.
No changes were observed in cellular morphology in WT mice at any examined time point. However, S193A mice showed progressive initiation of liver cancer starting from 25 weeks. At 25 weeks post-DEN injection, S193A livers had microscopic preneoplastic foci; at 28 weeks, the neoplastic foci were larger in size; and by 30 weeks, tumors were grossly and morphologically identified as neoplastic HCC ( Fig. 2A-C) . The microscopic foci were defined as regions that show cancer-specific liver morphology. Interestingly, we also observed perisinusoidal fibrosis inside the grossly visible tumor nodules at 28 weeks post-DEN injection (Fig. 2B) . Ultimately, examination of the dysplastic foci revealed that S193A livers develop early HCC.
LIVER CANCER OF DEN-TREATED S193A MICE SHOWS A SIGNATURE OF AGGRESSIVE HBL
We next examined molecular alterations in the livers of DEN-treated S193A mice at 28 weeks post-DEN injections. In WT mice, C/EBPa phosphorylated at S193 is degraded by Gank, which is activated by the reduction of FXR. (19) (20) (21) Therefore, we examined the FXR-Gank pathway in DEN-treated WT and S193A mice. Figure 2D ,E shows that FXR is reduced and Gank is elevated in WT and S193A DEN-treated mice. Surprisingly, levels of C/EBPa protein are elevated in S193A DEN-treated mice despite the reduction of C/ EBPa mRNA (Supporting Fig. S1 ). Because Gank triggers degradation of C/EBPa, (19) we performed co-IP studies and found no interaction of the S193A mutant with Gank, while WT C/EBPa does interact with Gank (Fig. 2D) . We conclude that the S193A mutant is elevated in DEN-treated S193A mice because it is protected from Gank-mediated degradation.
Because C/EBPa-Rb complexes are abundant in aggressive HBL, we examined these complexes in DEN-treated S193A mice. Similar to aggressive HBL, we detected an elevation in optical density in the fractions of SEC which contain high-MW protein-protein complexes (Fig. 2F) . Examination of C/EBPa and Rb revealed that a portion of each of these proteins is located in this high-MW region of SEC and that C/ EBPa-Rb complexes are located here (Fig. 2F, right) . A similar analysis of untreated S193A mice showed that the optical density profile is almost identical to that in WT mice. Western blotting did not detect C/EBPa in high-MW fractions of SEC of untreated S193A mice (Fig. 2F ). This result shows that C/EBPa-Rb complexes are not detectable in S193A mice prior to DEN treatment. It is likely that these complexes are formed in response to DEN treatment and perhaps are involved in chromatin remodeling at the stages of formation of tumor foci (see below). Thus, these studies demonstrated that, similar to aggressive HBL, liver cancer in DEN-treated S193A mice is characterized by an elevation of the mutant C/EBPa, which forms complexes with Rb. Importantly, these results confirmed that the DEN-S193A model is an appropriate tool for the study of mechanisms of aggressive HBL.
MICROSCOPIC PRENEOPLASTIC FOCI OF S193A MICE ARE HIGHLY PROLIFERATIVE AND EXPRESS MARKERS OF LIVER CANCER
We next analyzed microscopic tumor nodules in livers of S193A mice that are formed at 25 and 28 weeks after DEN treatment. Hematoxylin and eosin staining showed nonencapsulated large cells surrounding the central veins with some pleomorphism compared to hepatocytes in background regions (Fig. 3A,B) . Immunoexpression of ki67-positive and cyclin D1-positive hepatocytes revealed that the microscopic dysplastic foci are highly proliferative (Fig. 3A-C) . Dysplastic foci of S193A mice are characterized by an increase of cytokeratin 19-positive and AFP-positive cells. Thus, we conclude that dysplastic regions of livers of DEN-treated S193A mice contain high numbers of proliferating hepatocytes that express markers of hepatocarcinogenesis.
INITIATION OF LIVER CANCER IN DEN-TREATED S193A MICE IS CHARACTERIZED BY APPEARANCE OF ATYPICAL HEPATOCYTES
We next examined hepatocytes within the microscopic dysplastic foci of S193A-DEN-treated mice by staining with Abs to HNF4a (Fig. 4A) . Dysplastic foci revealed a significant reduction in the number of (Fig. 4B) . We call these morphologically distinct hepatocytes potential tumor-initiating hepatocytes (PTIHs).
We next examined if the PTIHs are proliferative by staining with cyclin D1. We found that cyclin D1-positive PTIHs are located mainly within dysplastic foci of S193A mice (Fig. 4C) . Around 50% of type 3, 4, and 5 hepatocytes within tumor nodules express high levels of cyclin D1 (Supporting Fig. S2 ). Interestingly, cyclinD1 is not detected within intranuclear inclusions of type 5 hepatocytes. To determine if these PTIHs might exist before formation of dysplastic foci, we examined the background of S193A and WT DEN livers after 28 weeks post-DEN injection. Hematoxylin and eosin and HNF4a staining indicated that type 4 and 5 hepatocytes are rare in background regions of DEN-treated S193A mice and that they are located around the central vein (Fig. 4D) . In the case of WT-DEN-treated mice (n 5 5), we found only two regions with type 4 and 5 hepatocytes located around the central vein (Fig. 4E) . We suggest that hepatocyte types 4 and 5 in background regions of DEN-treated S193A mice and in livers of DENtreated WT mice mark the areas where carcinogenic dysplastic foci will be further developed. We conclude that the very early stage of DEN-mediated liver cancer includes the initiation of the transformation of hepatocytes, leading to the formation of preneoplastic foci (Fig. 4F) . 
C/EBPa-S193A MICE DEVELOP SPONTANEOUS LIVER CANCER WITH BACKGROUND SECTIONS THAT CONTAIN PTIHs
We next examined tumor formation in S193A mice with increasing age. In 17-month-old S193A mice, we observed increased rates of proliferation in all S193A mice (18 animals) and development of liver cancer in 25% of S193A mice (Fig. 5A) . None of the examined WT mice (15 mice) developed liver cancer at this age.
Supporting Fig. S3 shows elevation of BrdU-positive hepatocytes and cyclin D1 in 17-month-old WT and S193A mice that did not have liver cancer. Immunostaining revealed that tumor nodule sections are negative for HNF4a, while the background sections are positive (Fig. 5B) . The majority of hepatocytes with HNF4a-negative intranuclear inclusions (type 5) are located alongside the tumor nodules, while type 4 hepatocytes are located at a relatively long distance from tumor nodules. This location of PTIHs suggests that type 5 hepatocytes are likely to occur at the last step of hepatocyte conversion to cancer cells. Figure 5C summarizes the studies of hepatocytes in tumor sections of S193A mice.
INTRANUCLEAR INCLUSIONS OF TYPE 5 HEPATOCYTES ARE NEGATIVE FOR C/EBPa AND HNF4a BUT POSITIVE FOR STEM CELL MARKER DLK1
We next examined proteins that might be expressed within intranuclear inclusions of type 5 hepatocytes and found that the nuclei of type 5 hepatocytes are positive for HNF4a and C/EBPa but negative for the stem cell marker DLK1. However, intranuclear inclusions are negative for HNF4a and C/EBPa but positive for DLK1 (Fig. 5D,E) . Background (nontumor) regions of DEN-treated S193A mice also contain DLK1-positive hepatocytes; however, the number of these cells was very low ( Fig. 5F; Supporting Fig. S4 ). Costaining hepatocyte type 5 cells with Abs to HNF4a and DLK1 confirmed that intranuclear inclusions are DLK1-positive and do not express HNF4a (Fig. 6A) . There are three kinds of DLK1-positive inclusions: one is partially positive for DLK1, second on the border, and the third within entire inclusions (Fig. 6B) . The process of cell transformation requires energy; therefore, we stained the hepatocytes with periodic acid-Schiff and found that 65% of type 5 hepatocytes contain glycogen inside intranuclear inclusions (Fig. 6C) . Costaining of the hepatocytes with the marker of heterochromatin histone H3 K9-trimethyl and bis-benzimide (DNA) revealed that type 4 and 5 hepatocytes contain enriched heterochromatin structures (Fig. 6D) , suggesting that C/EBPa-S193A-dependent alterations of chromatin structure are involved in dedifferentiation of hepatocytes.
ISOLATION AND CHARACTERIZATION OF PTIHs
DLK1 is observed inside intranuclear inclusions of PTIHs and is not acceptable for interactions with Abs in intact cells for flow-cytometric analysis. Therefore, we used a second characteristic of PTIHs, which is a multinucleated phenotype (Fig. 7A) . We next visualized multinucleated PTIHs by staining with b-catenin, which is located in membranes and precisely outlines the cells. DEN-treated WT livers contained roughly 0.2% of such hepatocytes, a majority of which contained three nuclei. However, the fraction of hepatocytes with three or more nuclei in control saline-treated S193A livers is 3-fold higher and reaches 0.7%. In the tumor nodules of S193A DEN-treated livers, the fraction of hepatocytes with three or more nuclei represents up to 1.2%-1.4% (Fig. 7B,C) . The majority of multinucleated S193A hepatocytes display a shape of the cells which is consistent with fusion of hepatocytes.
We next purified multinucleated hepatocytes from liver of S193A mice with spontaneous cancer using flow cytometry. Hepatocytes were sorted on the basis of cell size and DNA content. The portion of multinucleated hepatocytes in S193A livers is dramatically higher than that in livers of WT mice (Fig. 7D) . Purified hepatocytes were then plated and examined for proliferative capabilities. In these experiments, we plated an identical number of cells with a density of 20%-30%. Hepatocytes of WT livers did not proliferate, although they adhered to the plates. On the contrary, sorted hepatocytes from tumors of S193A mice proliferated and had around 60%-70% density at day 5 after plating (Fig. 7D, right) . Unfortunately, further maintenance of these hepatocytes was not possible because cells started to die 5 days after plating.
Given the limited number of sorted large hepatocytes, we performed additional experiments with single-cell suspensions of total cells. While single-cell suspension from WT mice did not show expansion of cells and proliferation, the cells from tumors of S193A mice showed an increased rate of proliferation by forming multicell colonies. We found that a portion of cells from S193A tumors also formed multinucleated cells, which is consistent with cell fusion (Fig. 7E) . We also found that cells from S193A tumors have a dramatic reduction of mRNAs of tumor suppressors C/EBPa, p53, HNF4a, and CUGBP1, while markers of stem cells (epithelial cell adhesion molecule, cyclindependent kinase 4, octamer 4, and AFP) are increased (Fig. 7F) .
PTIHs ARE ABUNDANT IN AGGRESSIVE PEDIATRIC LIVER CANCER, IN LIVER CANCER OF Pten/p53 DOUBLE KNOCKOUT MICE, AND IN A PATIENT WITH HIGH RISK FOR DEVELOPMENT OF CANCER
Dephosphorylated C/EBPa is elevated in patients with aggressive HBL (Fig. 1) . Therefore, we asked if these patients might have C/EBPa-dependent PTIHs. Ki67 staining showed that all samples have a high rate of liver proliferation in both background and tumor nodule sections. HNF4a staining demonstrated that tumor regions of aggressive HBL contain areas which are negative and positive for HNF4a ( Fig. 8A ; Supporting Fig. S5 ). HNF4a-positive hepatocytes within background regions contain type 4 and type 5 PTIHs. Our data with S193A mice show that the appearance of hepatocytes with DLK1-positive intranuclear inclusions is a very early event in the development of liver cancer. Therefore, we next asked if the hepatocytes with intranuclear inclusions in HBL patients with severe cancer might still express DLK1 inside inclusions. Staining with DLK1 Abs showed that the majority of hepatocytes with intranuclear inclusions lost expression of DLK1; however, a small portion of type 5 hepatocytes are still positive for DLK1. Figure  8A (bottom panel) shows typical images of positive and negative hepatocytes in HBL samples with severe liver cancer. It is important to note that all available HBL samples are from patients who underwent chemotherapy. It is possible that the low number of hepatocytes with DLK1-positive inclusions might be the result of these treatments.
We next investigated hepatocytes in double knockout (DKO) Pten/p53 mice that develop liver cancer rapidly. Approximately 6% of mice have metastases, primarily in lung. (30) In liver tumor sections of Pten/ p53 DKO mice, we have observed the accumulation of HNF4a-positive multinucleated hepatocytes (types 3-5) and abundant hepatocytes with intranuclear HNF4a-negative inclusions (Fig. 8B , "a" and "b"). To determine C/EBPa levels and the phosphorylation status of C/EBPa, we performed western blotting examination of nuclear proteins from WT and Pten/p53 tumors. These studies demonstrated that, similar to DEN-treated S193A mice, levels of C/EBPa are elevated but that C/EBPa is not phosphorylated at Ser193 in liver tumors of Pten/p53 mice (Fig. 8B, "c") . We found that multinucleated hepatocytes are also abundant in tumor sections of lung metastases (Fig.  8C) . In addition to this mouse model, we detected PTIHs in WT mice that spontaneously develop liver cancer with age (Supporting Fig. S6) .
We next asked if we could detect the PTIHs in patients with high risk for liver cancer prior to having symptoms of liver cancer. Investigations of the biopsies of a young individual, who has telomere shortening secondary to dyskeratosis congenita, showed dysplastic foci that look like early tumor nodules (Fig. 8D) . Within these foci, we detected cells with intranuclear inclusions similar to those observed in the very early tumor nodules of DEN-treated C/EBPa-S193A mice. Figure 8E summarizes the morphology of hepatocytes in the dysplastic foci of this patient. Taken together, examination of patients with aggressive HBL, liver cancer in Pten/p53 DKO mice, spontaneous liver cancer in WT mice, and a patient with a high risk of liver cancer showed that PTIHs are abundant in these cancers and in the high-risk liver cancer patient.
Discussion
Although the initial studies suggested a critical role of progenitor cells in the development of liver cancer, recent findings have questioned their role in liver cancer. (1) (2) (3) 31) In this study, we performed a systemic analysis of several mouse models of liver cancer, a large cohort of pediatric liver cancer, and a patient who has a high risk for the development of liver cancer. Figure  8F summarizes our major findings within C/EBPadependent early preneoplastic foci. The main result is that these regions are the origin of HCC and aggressive HBL, where dedifferentiation of hepatocytes into PTIHs takes place. The first event is the activation of C/EBPa transcription, leading to elevation of C/EBPa protein. The next step includes the dephosphorylation of C/EBPa at Ser193 (Ser190 in human protein), which converts C/EBPa into a protein with oncogenic activities. The dephosphorylated S193/ S190-C/EBPa further causes a cascade of transformations of hepatocytes into PTIHs.
The majority of our molecular cause-effect data for this hypothesis were obtained in genetically modified animal models. Although these studies are critical and important, the question remains as to how dephosphorylated S190-C/EBPa is activated in naturally occurring HCC and HBL and if this activation causes dedifferentiation of hepatocytes in human settings. This is a very challenging question because all human liver cases are diagnosed at severe stages and there are only indirect and correlative approaches to examine this issue. In this regard, we have detected dephosphorylated S190-C/EBPa isoform and a signature of C/EBPa-dependent molecular events in background (not tumor) regions of the livers in several patients with HBL. These alterations are similar to those observed in S193A-DEN-treated mice. Thus, we conclude that the preneoplastic foci with PTIHs are the origin of aggressive HBL and HCC.
